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From 2008–2013, the European indication for panitumumab required that patients’ tumor
KRAS exon 2 mutation status was known prior to starting treatment. To evaluate physician
awareness of panitumumab prescribing information and how physicians prescribe panitu-
mumab in patients with metastatic colorectal cancer (mCRC), two European multi-country,
cross-sectional, observational studies were initiated in 2012: a physician survey and a med-
ical records review. The first two out of three planned rounds for each study are reported.
Methods
The primary objective in the physician survey was to estimate the prevalence of KRAS test-
ing, and in the medical records review, it was to evaluate the effect of test results on patterns
of panitumumab use. The medical records review study also included a pathologists’
survey.
Results
In the physician survey, nearly all oncologists (299/301) were aware of the correct panitu-
mumab indication and the need to test patients’ tumor KRAS status before treatment with
panitumumab. Nearly all oncologists (283/301) had in the past 6 months of clinical practice
administered panitumumab correctly to mCRC patients with wild-type KRAS status. In the
medical records review, 97.5% of participating oncologists (77/79) conducted a KRAS test
for all of their patients prior to prescribing panitumumab. Four patients (1.3%) did not have
tumor KRASmutation status tested prior to starting panitumumab treatment. Approximately
one-quarter of patients (85/306) were treated with panitumumab and concurrent oxaliplatin-
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containing chemotherapy; of these, 83/85 had confirmed wild-type KRAS status prior to
starting panitumumab treatment. All 56 referred laboratories that participated used a Con-
formité Européenne-marked or otherwise validated KRAS detection method, and nearly all
(55/56) participated in a quality assurance scheme.
Conclusions
There was a high level of knowledge amongst oncologists around panitumumab prescribing
information and the need to test and confirm patients’ tumors as being wild-type KRAS prior
to treatment with panitumumab, with or without concurrent oxaliplatin-containing therapy.
Introduction
Anti-epidermal growth factor receptor (EGFR) monoclonal antibodies (mAbs), such as panitu-
mumab (Vectibix1, a recombinant, fully human IgG2 mAb) and cetuximab (Erbitux1, a
recombinant, chimeric mouse/human IgG1 mAb), bind with high affinity and specificity to the
EGFR, and have been shown to be effective across all lines of treatment in metastatic colorectal
cancer (mCRC) [1–7]. Reports of improved efficacy with panitumumab and cetuximab in
patients with wild-type versus mutant or unknown KRAS exon 2 status [8–15] led to the
requirement for physicians to determine a patient’s tumor KRASmutation status prior to start-
ing treatment with EGFR inhibitors. Physicians can now determine the most appropriate treat-
ment option for individual patients with mCRC, based upon the molecular profile of their
tumor.
Panitumumab was first approved in Europe in December 2007 as monotherapy to treat
patients with wild-type KRAS exon 2 mCRC who had failed on prior fluoropyrimidine-, oxali-
platin-, and irinotecan-containing chemotherapy regimens, based upon phase III clinical data
[6,8]. Educational materials for panitumumab have been distributed to physicians since 2009,
making them aware of the appropriate prescribing information and the need for KRASmuta-
tion status to be determined by an experienced laboratory prior to prescribing panitumumab.
In November 2011, data from two additional phase III studies led to the European panitumu-
mab license being expanded to include use in patients with wild-type KRAS exon 2 mCRC in
the first-line setting combined with FOLFOX [16], and the second-line setting combined with
FOLFIRI [17]. Within the panitumumab licensed indication, concurrent treatment with oxali-
platin-containing chemotherapy in patients with mutant or unknown KRASmCRC status was
contraindicated, due to detrimental effects on progression free survival and overall survival.
Previous physician surveys have found that in 2010, when guidelines first recommended
testing for KRAS status [18,19], the adoption of KRAS testing prior to treating patients with
EGFR inhibitors varied widely [20–22]. In 2010, 73% (326/448) of participating physicians in
Europe reported undertaking appropriate KRAS testing when mCRC was diagnosed, compared
with 63% (160/256) in Latin America and 20% (28/139) in Asia [20]. However, there was a
rapid and widespread adoption of KRAS testing prior to treating patients with EGFR inhibitors
(3% in 2008; 47% in 2009; 69% in 2010), with results available quickly (within 15 days) for
more than 80% of patients [20]. In the US, a survey carried out in 2010 reported that of 1,242
physicians responding, only one-fifth of those who had treated mCRC had ordered or recom-
mended KRAS testing [21]. In contrast in another study, a more targeted identification of
oncologists treating mCRC found that in 2010 all oncologists (34/34) tested tumor KRAS status
[22].
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Medical records review studies carried out in 2010 reported that over 94% of patients were
being tested for tumor KRAS status prior to being treated with EGFR-targeted therapies
[23,24]. In 93 sites from France, 94% of 1,044 patients being treated with cetuximab for CRC
had been tested for tumor KRAS status, with wild-type KRAS confirmed in 95% of tested
patients [23]. In the US, there was rapid uptake of KRAS tumor testing by 2010 in one study,
with 97% of 1,188 patients with mCRC being tested in 2010 compared with 7% of patients
being tested in 2006 [24].
In order to evaluate physician awareness of the prescribing information for panitumumab
and how physicians prescribe panitumumab in Europe, two studies were initiated in 2012: a
physician survey evaluating oncologists’ knowledge of the licensed indication for panitumu-
mab, and a medical records review of patients with mCRC treated with panitumumab to evalu-
ate how oncologists prescribe panitumumab. The first two rounds focused upon KRAS exon 2
status and are reported here. In July 2013, based upon improved outcomes in patients with
wild-type versus mutant or unknown tumor RAS status [25], the European license for panitu-
mumab was refined to target panitumumab treatment to patients with wild-type RASmCRC.
The ongoing third and final rounds of each study are focusing on tumor RAS (KRAS exons 2/
3/4 and NRAS exons 2/3/4) testing, and will be reported separately in a future publication.
Both studies will help to understand the level of acceptance of tumor KRAS/RAS testing by cli-
nicians during their decision processes around treating with panitumumab.
Materials and Methods
Study participants
A physician survey and a medical records review were designed in Europe: both were multi-
country, cross-sectional, observational studies with practicing oncologists who had prescribed
panitumumab to mCRC patients in the previous 6 months. Rounds 1 and 2 (evaluating KRAS
testing) were conducted between September 2012 and December 2013. Round 3 (evaluating
RAS testing) is currently being conducted for both studies in 2014 and 2015.
In Round 1, physicians in five countries (France, Germany, Italy, Spain, and the Czech
Republic) were invited to participate. Four additional countries (Belgium, Denmark, The Neth-
erlands, and Sweden) were included in Round 2 to increase representation of countries in
Europe. In both rounds of each study, physicians were screened by telephone using standard-
ized questionnaires to determine eligibility.
The sampling list used in Round 1 was based on a healthcare industry database provider
(Cegedim) medical marketing database and included physician contact details that were not fil-
tered by specialty. Physicians were randomly selected for inclusion in the study from this list.
The inclusion of physicians who were not oncologists in the study population partly explains
the low response rate observed in Round 1 of the study. In Round 2 of the medical chart review
the sampling list used included the medical marketing database filtered by specialty in addition
to lists of colorectal cancer physicians. This approach allowed for a more targeted sampling of
oncologists and led to a higher physician response rate in Round 2 of the chart review than
observed in Round 1.
In order to obtain data on pathology testing, participating oncologists in the medical records
review study were asked permission for the investigator to approach the pathology laboratories
which carried out KRASmutation tests, in order to send them a pathology survey to complete.
Study protocols and informed consent forms (ICF) were reviewed and approved by the
local Institutional Review Board or Ethical Review Board in each country before the studies
began, as required. As agreed with the ethical committees, in France and The Netherlands
signed ICFs were not required, only verbal ICF (recorded in the patient’s file). ICFs were
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required in Germany (reviewed and approved by the Ethik-Kommission der Bayerischen
Landesärztekammer), Italy (reviewed and approved by the EC Azienda AOU S. Maria della
Misericordia di Udine), Spain (reviewed and approved by the Comite Etico de Investigacion
Clinica H.G.U. Gregorio Maranon), Czech Republic (reviewed and approved by the Eticka
Komise Masarykova Onkologickeho Ustavu, Brno), Belgium (reviewed and approved by the
Medical Ethics Committee des Cliniques Saint-Joseph, Liege) and Sweden (reviewed and
approved by the Regional Ethic Committee Board in Sweden—Karolina Institutet/ Solna). Eth-
ics Committee approval was not required in Denmark, but a signed ICF was required in all
Danish sites.
Inclusion criteria for participating physicians
Physician survey. Practicing oncology specialists were eligible if they had treated at least
five (Round 1) or three (Round 2) new or continuing patients with mCRC in the last 3 months
and prescribed panitumumab in the previous 6 months.
Medical records review. Practicing oncologists who had treated at least five (Round 1) or
three (Round 2) new or continuing patients with mCRC in the last 3 months, and had pre-
scribed panitumumab to treat new or continuing patients with mCRC in the past 6 months
were eligible. Only one oncologist per medical center could participate for each round of the
study.
Exclusion criteria for participating physicians
In Round 2 of each study, physicians were excluded if they had already taken part in Round 1.
Physicians were excluded from the physician survey if they had taken part in the medical
record review (Round 1 or 2). Physicians were excluded from the medical record review if they
had taken part in the physicians survey (Round 1 only).
Note that in Round 2 of the medical records review, a more targeted sampling of oncologists
was introduced with physicians from specialties that do not treat mCRC being excluded. In
addition, in both studies, the number of new or continuing patients with mCRC requiring
treatment in the last 3 months was reduced from at least five in Round 1, to at least three in
Round 2. These changes were introduced in order to improve physician response rates.
Inclusion criteria for patients
In the medical records review, eligible patients must have received panitumumab (outside of a
clinical trial setting) for the treatment of mCRC during the 6-month period prior to the time
when medical records were obtained, and have provided written consent to allow access to
their medical records (if local laws required it). Informed consent was obtained from a legally
acceptable representative of deceased patients, where necessary, to allow access to their medical
records for the purpose of this study.
Study objectives
Physician survey. The primary objective is to assess oncologists’ knowledge of the appro-
priate licensed indication for panitumumab in mCRC patients regarding tumor KRAS status in
selected European countries. Specific primary objective measures are to evaluate oncologists’
knowledge: of the licensed indication for panitumumab, which is for the treatment of patients
with wild-type KRASmCRC in first line combined with FOLFOX, in second line combined
with FOLFIRI in patients who have received first–line fluoropyrimidine-based chemotherapy
(excluding irinotecan), and as monotherapy after failure of fluoropyrimidine-, oxaliplatin-, and
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irinotecan-containing chemotherapy regimens; that testing tumor KRASmutation status
should be performed prior to starting treatment with panitumumab; that panitumumab is not
indicated for mCRC patients with mutant or unknown KRAS tumor status; that panitumumab
should not be administered in combination with oxaliplatin-containing chemotherapy in
mCRC patients with mutant or unknown KRAS tumor status. An additional objective measure
is to characterize the results of the survey in each round to evaluate whether there are any dif-
ferences between rounds.
Medical records review. The primary objective is to estimate the prevalence of KRAS test-
ing and the impact of KRAS test results on patterns of panitumumab use in patients with
mCRC treated with panitumumab in selected European countries, following changes in the
licensed indication regarding the risk of panitumumab use in mCRC patients with mutant
KRAS tumors. The primary objective measures include: the estimated proportion of patients
with mCRC tested for KRAS status prior to treatment with panitumumab; the proportion of
tested patients treated with panitumumab who had mutant, wild-type, or unknown tumor
KRAS status; the estimated proportion of patients with mCRC tested for KRAS status prior to
treatment with panitumumab who were treated concurrently with oxaliplatin-containing che-
motherapy; the proportion of tested patients treated with panitumumab concurrently with
oxaliplatin-containing chemotherapy who had mutant, wild-type, or unknown tumor KRAS
status. Secondary objective measures include the estimated proportion of: oncologists who
agree to participate in the study; oncologists who conduct a KRAS test prior to prescribing
panitumumab (in those patients with mCRC who had been treated with panitumumab); labo-
ratories that tested mCRC KRAS status for those patients who were treated with panitumumab
who i) participate in the European Society of Pathology (ESP) Quality Assurance (QA)
Scheme, or are certified by an ESP-approved accreditation body, and ii) use a Conformité Eur-
opéenne (CE)-marked or otherwise validated KRAS detection method. An additional objective
measure is to characterize the results of each round of the medical records review, and to evalu-
ate whether there are any differences between rounds.
Data collection
Physician survey. In each round of survey, telephone interviews with eligible participating
oncologists were conducted by trained study staff using a standardized questionnaire and fol-
lowing consistent procedures and data collection. The questionnaire was carefully translated to
ensure that the content and the way of asking questions was consistent across countries. Two
pilot interviews were conducted in each country in Round 1 to ensure that all questions were
well targeted and correctly understood; questions were reviewed and modified as needed,
depending on the outcome of the pilot interviews.
Medical records review. Medical information relating to panitumumab (including but not
limited to 3 months before and after the first dose of panitumumab) and tumor KRAS testing
was abstracted and anonymized at the site from medical records for transfer into standardized
electronic case report forms. Abstracted and anonymized data were checked by trained data
extractors prior to being included in the data analysis. Two pilot abstractions were conducted
in each country prior to Round 1, to ensure all questions were well targeted and correctly
understood, with modifications made as required.
Statistical analysis
In both studies, no formal hypothesis testing was conducted and the data analysis was descrip-
tive in nature. For the categorical study endpoints described above, the count and proportion
(%) in each category, based on the appropriate denominator, were calculated. The 95%
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confidence intervals for the proportions are based on a normal approximation to the binomial
distribution.
Results
Physician response rate and baseline characteristics
Physician survey. There were low responses in the first two rounds of the physician sur-
vey, with 10.8% (441/4,075) of physicians responding to the screening questionnaire (Fig 1A).
In Rounds 1 and 2 combined, 301 eligible physicians who responded to the screening ques-
tionnaire agreed to participate (Fig 1A), and their characteristics were generally similar
between rounds (Table 1). Participating oncologists were mainly from university/training hos-
pitals (41.5%; n = 125) and general/regional hospitals (30.2%; n = 91), with the median
(Q1–Q3) number of in-patient beds being 400 (100–773) (Table 1). The median (Q1–Q3)
number of years of experience as a practicing oncologist specialist was 11 (7–16), with oncolo-
gists treating 40 (25–70) mCRC patients in the last 3 months (Table 1). Over three quarters
(78.1%; 235/301) of participating oncologists recalled having received educational material
regarding KRAS testing.
Medical records review. In Round 1, low responses to the screening questionnaire (8.6%;
105/1,218) were observed (Fig 1B). However, in Round 2 response rates increased (60.9%; 56/
92) as a result of changes in methodology and inclusion criteria outlined in the Methods sec-
tion, with all 56 oncologists responding to the screening questionnaire being eligible (40 were
not eligible in Round 1).
Seventy-nine eligible physicians who responded to the screening questionnaire agreed to
participate (Fig 1B). The characteristics of those who participated were generally similar in
Rounds 1 and 2, though the proportion based in private practice halved from 58.8% (20/34) in
Round 1 to 28.9% (13/45) in Round 2 (Table 1). The median (Q1–Q3) number of years of
experience as a practicing oncologist specialist was 13 (6–16) and 19 (13–24) years in Rounds 1
and 2, respectively.
Three hundred and six patient records from the 79 participating oncologists in both rounds
of the medical records review were evaluated. Two-thirds of patients were male (66.7%; 204/
306), and approximately one-quarter (23.9%; 73/306) were 75 years of age or older (Table 2).
Just over one-quarter were receiving concurrent panitumumab and oxaliplatin-containing
therapy (27.8%; 85/306) (Table 2).
Physician’s understanding of who, and how, to treat with panitumumab
Physician survey results: Awareness of the licensed indication and testing for KRAS sta-
tus before starting treatment with panitumumab. Nearly all oncologists were aware of the
need to test patients with mCRC for KRAS status before treatment with panitumumab (99.3%;
299/301) (Table 3). Of the two remaining oncologists, one did not consider KRAS testing to be
appropriate, and the other provided no response. Nearly all oncologists (99.0%; 298/301) were
aware of the correct indication for panitumumab for treatment of mCRC patients with wild-
type KRAS tumors; two oncologists responded for the treatment of patients with mutant
mCRC KRAS tumors, and one gave an invalid multiple response. Almost all (97.7%; 294/301)
oncologists were aware of all their patients’ tumor KRAS status prior to treatment with panitu-
mumab (Table 3). Six oncologists were unaware of their patients’ tumor KRASmutation status
prior to treatment with panitumumab, and the other gave a missing response.
Correct administration of panitumumab: Nearly all oncologists (94.0%; 283/301) had
administered panitumumab correctly to all their mCRC patients in the past 6 months of clini-
cal practice (those with known wild-type KRAS status prior to first dose of panitumumab)
Panitumumab Use and KRAS Testing in mCRC
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(Table 3). Of the responses from the remaining 18 oncologists, 15 (5.0%) had administered
panitumumab to at least one patient with mutant or unknown KRAS status in the past 6
months of clinical practice, two (0.7%) were unsure, and one (0.3%) gave a missing response.
The most frequent influencing factors cited for treating patients with mutant KRAS status were
the patient’s medical status (n = 8) and other (n = 6: not concerned with KRASmutation type
Fig 1. Physician disposition for the A) physician survey and B) medical records review studies.
doi:10.1371/journal.pone.0140717.g001
Panitumumab Use and KRAS Testing in mCRC
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[n = 3]; administered when KRAS status was unknown [n = 1]; special [13] mutation [n = 1];
good results with other patients [n = 1]). The most frequent influencing factors cited for treat-
ing patients with KRAS status unknown were time to obtain KRAS results (n = 6), tissue not
available / insufficient tissue available (n = 4) and patient’s status or medical condition (n = 4).
It should be noted that multiple reasons could be given.
Of the 301 participating oncologists, 164 (54.5%) had administered panitumumab concur-
rently with oxaliplatin-containing therapy to at least one mCRC patient in the past 6 months
of routine clinical practice (Table 3). Of these, 10 (6.1%) oncologists had administered
Table 1. Oncologist demographics in the physician survey andmedical records review studies.
Physician survey Medical records review
Round 1 Round 2 Total Round 1 Round 2 Total
N = 150 N = 151 N = 301 N = 34 N = 45 N = 79
Country, n (%)
France 50 (33.3) 39 (25.8) 89 (29.6) 14 (41.2) 9 (20.0) 23 (29.1)
Germany 35 (23.3 44 (29.1) 79 (26.2) 15 (44.1) 11 (24.4) 26 (32.9)
Italy 28 (18.7) 18 (11.9) 46 (15.3) 1 (2.9) 5 (11.1) 6 (7.6)
Spain 25 (16.7) 19 (12.6) 44 (14.6) 3 (8.8) 5 (11.1) 8 (10.1)
Czech Republic 12 (8.0) 6 (4.0) 18 (6.0) 1 (2.9) 4 (8.9) 5 (6.3)
Belgium 6 (4.0) 6 (2.0) 3 (6.7) 3 (3.8)
Denmark 5 (3.3) 5 (1.7) 3 (6.7) 3 (3.8)
Netherlands 9 (6.0) 9 (3.0) 2 (4.4) 2 (2.5)
Sweden 5 (3.3) 5 (1.7) 3 (6.7) 3 (3.8)
Type of institution, n (%)
General or regional
hospital 52 (34.7) 39 (25.8) 91 (30.2) 8 (23.5) 12 (26.7) 20 (25.3)
Oncology clinic/institute 16 (10.7) 14 (9.3) 30 (10.0) 0 7 (15.6) 7 (8.9)
Private clinic/hospital 27 (18.0) 23 (15.2) 50 (16.6) 20 (58.8) 13 (28.9) 33 (41.8)
University/training
hospital 51 (34.0) 74 (49.0) 125 (41.5) 4 (11.8) 9 (20.0) 13 (16.5)
Other 4 (2.7) 1 (0.7) 5 (1.7) 2 (5.9) 4 (8.9) 6 (7.6)
Size of intitution (number of inpatient beds)
n 141 151 292 28 42 70
Mean (SD) 383.4 (377.1) 596.5 (515.5) 493.6 (465.6) 319.3 (496.1) 315.3 (549.9) 316.9 (525.4)
Median (Q1–Q3) 300.0 (50.0–600.0) 550.0 (200.0–800.0) 400.0 (100.0–772.5) 69.5 (7.0–350.0) 50.0 (17.0–400.0) 50.0 (17.0–400.0)
Number of years' experience as a practicing oncologist
n 149 151 300 34 45 79
Mean (SD) 12.8 (7.7) 12.2 (6.5) 12.5 (7.1) 12.3 (6.1) 18.2 (9.1) 15.7 (8.5)
Median (Q1–Q3) 12.0 (7.0–16.0) 11.0 (7.0–15.0) 11.0 (7.0–16.0) 12.5 (6.0–16.0) 19.0 (13.0–24.0) 15.0 (10.0–20.0)
Number of mCRC patients treated by the oncologist in the previous 3 months
n 150 151 301 34 45 79
Mean (SD) 58.7 (58.3) 59.4 (57.3) 59.0 (57.7) 75.1 (96.3) 45.1 (33.1) 58.0 (69.0)
Median (Q1–Q3) 45.0 (20.0–60.0) 40.0 (25.0–70.0) 40.0 (25.0–70.0) 47.5 (20.0–90.0) 30.0 (20.0–60.0) 36.0 (20.0–70.0)
Number of mCRC patients treated with panitumumab in the last 6 months
n NsR NR NR 34 45 79
Mean (SD) 9.4 (6.0) 9.0 (10.9) 9.2 (9.1)
Median (Q1–Q3) 8.0 (6.0–10.0) 6.0 (5.0–8.0) 6.0 (5.0–10.0)
mCRC, metastatic colorectal cancer; NR, not recorded; SD, standard deviation.
doi:10.1371/journal.pone.0140717.t001
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panitumumab simultaneously with oxaliplatin-containing chemotherapy to mCRC patients
with KRAS status mutant or unknown, and one oncologist was unsure (Table 3). There was no
indication from the free-text responses that these oncologists were unaware of the contraindi-
cation of administering panitumumab simultaneously with oxaliplatin-containing chemother-
apy to mCRC patients with tumor KRAS status unknown.
Differences in survey responses between rounds: There were no noticeable differences in the
results obtained for the physician survey between Rounds 1 and 2.
How oncologists treat patients with panitumumab based upon KRAS
testing
Medical records review results: Proportion of oncologists testing patients’ tumors for
KRAS status prior to treatment with panitumumab. Nearly all oncologists (97.5%; 77/79)
conducted a KRASmutation test for all their mCRC patients prior to prescribing
panitumumab.
Almost all patients (98.7%; 302/306) had been tested for KRASmutation status prior to
their first panitumumab dose, with wild-type KRASmutation status confirmed in 97.7% (299/
306) of patients (Table 4). Four patients (1.3%; all from two oncologists) had not been tested
for KRASmutation status prior to their first dose of panitumumab. One patient had a KRAS
test result (wild-type) dated after the first panitumumab dose (this patient was also receiving
concurrent oxaliplatin-containing chemotherapy). Three patients had no KRAS test result
available (tissue was not available/insufficient tissue available [1 patient], unaware of the need
for KRAS test [1 patient]; patient’s situation [1 patient]).
Three (1.0%) of the 302 patients tested for KRAS tumor status prior to their first dose of
panitumumab had mutant (n = 2) or unknown (n = 1) KRAS status (none were receiving con-
current oxaliplatin-containing therapy (Table 4).
Testing patients’ tumors for KRAS status prior to treatment with panitumumab and concur-
rent oxaliplatin-containing chemotherapy: Approximately one quarter of patients (27.8%; 85/
306) were treated with panitumumab and concurrent oxaliplatin-containing chemotherapy,
with nearly all of these patients (97.6%; 83/85) having a confirmed wild-type KRAS result prior
to starting treatment (Table 4).
Table 2. Patient demographics in the medical records review study.
All patients Round 1 Round 2 Total
N = 155 N = 151 N = 306
Sex—male, n (%) 96 (61.9) 108 (71.5) 204 (66.7)
Age (years)—mean (SD) 66.1 (11.0) 66.8 (10.9) 66.4 (10.9)
Age 65 years, n (%) 93 (60.0) 96 (63.6) 189 (61.8)
Age 75 years, n (%) 39 (25.2) 34 (22.5) 73 (23.9)
Patients receiving concurrent oxaliplatina Round 1 Round 2 Total
N = 53 N = 53 N = 85
Sex—male, n (%) 39 (73.6) 26 (81.3) 65 (76.5)
Age (years)—mean (SD) 63.5 (9.5) 64.4 (13.7) 63.8 (11.2)
Age 65 years, n (%) 29 (54.7) 19 (59.4) 48 (56.5)
Age 75 years, n (%) 7 (13.2) 8 (25.0) 15 (17.6)
SD, standard deviation.
aReceived oxaliplatin-containing chemotherapy during the interval from 7 days prior to the date of ﬁrst dose
of panitumumab, until 7 days after the last dose of panitumumab.
doi:10.1371/journal.pone.0140717.t002
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Laboratory use of validated KRAS detection methods: Participating oncologists were asked to
name the corresponding laboratories that analyzed the tumor samples. Of the 95 named labo-
ratories, 56 (58.9%) responded to the survey. All 56 laboratories (100%) used a CE-marked or
otherwise validated KRAS detection method, with 34 (60.7%) laboratories using non-commer-
cial tests that were not CE-marked, but were otherwise validated. Nearly all (98.2%; 55/56) par-
ticipated in at least one QA scheme (e.g. ESP QA scheme [10 (17.9%)], Directory of Molecular
Genetic External QA schemes in Europe [8 (14.3%)], United Kingdom National External QA
Service [4 (7.1%)], local or regional QA schemes such as the French Gen&Tiss scheme [25
(44.6%)], or other QA schemes [21 (37.5%)]).
Differences in medical record review responses between rounds: There were no noticeable dif-
ferences in the results obtained for the medical records review study between Rounds 1 and 2.
Table 3. Outcomes of testing for KRAS exon 2 in the physician survey study.
n (%)
(95% CI: %)
Round 1 Round 2 Total
All oncologists N = 150 N = 151 N = 301
Aware KRAS testing should be performed prior to 149 (99.3) 150 (99.3) 299 (99.3)
initiation of panitumumaba (98.0–100.0) (98.0–100.0) (98.4–100.0)
Aware of the correct indication for panitumumab 148 (98.7) 150 (99.3) 298 (99.0)
for treatment of mCRC patients with wild-type (96.8–100.0) (98.0–100.0) (97.9–100.0)
KRAS tumorsb
Aware of patients tumor KRAS status prior to 144 (96.0) 150 (99.3) 294 (97.7)
initiation of panitumumab treatment in the past (92.9–99.1) (98.0–100.0) (96.0–99.4)
6 months of routine clinical practicec
Administered panitumumab to only mCRC 143 (95.3) 140 (92.7) 283 (94.0)
patients with wild-type KRAS in the past 6 months (92.0–98.7) (88.6–96.9) (91.3–96.7)
of routine clinical practiced
Subset of oncologists who administered
panitumumab concurently with oxaliplatin- Round 1 Round 2 Total
containing chemotherapy N = 74 N = 90 N = 164
Administered panitumumab with concurrent 70 (94.6) 83 (92.2) 153 (93.3)
oxaliplatin-containing chemotherapy to only (89.4–99.7) (86.7–97.8) (89.5–97.1)
mCRC patients with wild-type KRAS in the past
6 months of routine clinical practicee
CI, conﬁdence interval; mCRC, metastatic colorectal cancer.
aOne oncologist responded that KRAS testing was not appropriate (Round 1), and one oncologist did not respond (Round 2).
bTwo oncologists responded for treatment of patients with mutant mCRC KRAS tumors (one in each round), and one gave an invalid multiple response
(Round 1).
cSix oncologists were unaware of patients’ tumor KRAS status prior to initiation of panitumumab treatment (Round 1), and one oncologist gave a missing
response (Round 2).
dFifteen oncologists had administered panitumumab to mCRC patients with mutant KRAS tumors or with tumor KRAS status unknown (seven in Round 1
and eight in Round 2), two oncologists gave a not sure response (Round 2), and one oncologist did not give a response (Round 2).
eTen oncologists had administered panitumumab with concurrent oxaliplatin-containing chemotherapy to mCRC patients with mutant KRAS tumors or with
tumor KRAS status unknown (three in Round 1 and seven in Round 2), and one oncologist gave a not sure response (Round 1).
doi:10.1371/journal.pone.0140717.t003
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Discussion
In the physician survey, amongst participating oncologists, nearly all those surveyed in 2012
and 2013 (99.3%; 299/301) were aware of the need to test tumor KRAS status before adminis-
tration of panitumumab to patients with mCRC. Nearly all oncologists (94.0%; 283/301) had
administered panitumumab correctly to all of their mCRC patients with wild-type KRAS sta-
tus, according to the label, in the past 6 months of clinical practice. In the medical records
review, nearly all oncologists (97.5%) conducted a KRAS test for all of their patients prior to
prescribing panitumumab. Importantly, tumor KRAS status was known in nearly all (98.7%)
patients prior to prescribing panitumumab (with or without oxaliplatin-containing therapy),
with tumor wild-type KRAS confirmed in 97.7% of patients. All corresponding laboratories
that responded to the pathologist survey used validated KRAS testing methods, and regularly
checked their testing methods versus QA schemes in place.
Fifteen of the 301 oncologists in the physician survey said that in the last 6 months of clini-
cal practice they had administered at least once panitumumab to mCRC patients when the
KRAS result was mutant or unknown. This proportion (5%) is higher in the survey than in the
chart review study in which 1% of the patients had mutant or unknown KRAS results at the ini-
tiation of panitumumab treatment. The physician survey records the number of physicians
who had administered panitumumab outside the label indication once or more in the last 6
months and therefore, did not capture the number patients treated according to the label as the
chart review did. Oncologists quoted a number of reasons for prescribing panitumumab (with
or without concurrent oxaliplatin-containing therapy) to patients with mutant or unknown
KRAS status, with the most frequent influencing factors being the patients’medical condition,
Table 4. Outcomes of testing for KRAS exon 2 in the medical records review study.
n (%)
(95% CI: %)
Round 1 Round 2 Total
All patients N = 155 N = 151 N = 306
Tested for KRAS status prior to ﬁrst dose of 153 (98.7) 149 (98.7) 302 (98.7)
panitumumaba (96.9–100.0) (96.9–100.0) (97.4–100.0)
Wild-type KRAS test result conﬁrmed prior to 152 (98.1) 147 (97.4) 299 (97.7)
ﬁrst dose of panitumumabb (95.9–100.0) (94.8–99.9) (96.0–99.4)
Subset of patients treated with concurrent Round 1 Round 2 Total
oxaliplatin-containing chemotherapyc N = 53 N = 32 N = 85
Tested for KRAS status prior to ﬁrst dose of 51 (96.2) 32 (100) 83 (97.6)
panitumumabd (91.1–100.0) 100.0–100.0) (94.4–100.0)
Wild-type KRAS test result conﬁrmed prior to 51 (96.2) 32 (100) 83 (97.6)
ﬁrst dose of panitumumab (91.1–100.0) (100.0–100.0) (94.4–100.0)
CI, conﬁdence interval; mCRC, metastatic colorectal cancer.
aThree patients did not have a KRAS test performed (one in Round 1 and two in Round 2), and one patient had a KRAS test performed after the ﬁrst dose
of panitumumab (Round 1).
bTwo patients had a mutant KRAS test result conﬁrmed prior to ﬁrst dose of panitumumab (one in Round 1 and one in Round 2) and one patient had an
unknown KRAS test result (Round 2).
cReceived oxaliplatin-containing chemotherapy at any time during the interval from 7 days prior to the date of ﬁrst dose of panitumumab, until 7 days after
the last dose of panitumumab.
dOne patient did not have a KRAS test performed (Round 1), and one patient had a KRAS test performed after the ﬁrst dose of panitumumab (Round 1).
doi:10.1371/journal.pone.0140717.t004
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that they were unconcerned by KRASmutation status, the availability of tumor tissue, and the
time taken for KRAS test results to be received. It appears that on rare occasions physicians are
using their clinical judgment and they do not adhere with the guidelines despite that they seem
to have a good knowledge of the label indication. Characteristics of patients such as co-morbid-
ity is a factor that has been shown in the past to influence physicians implementation of clinical
guidelines [25].
Low response rates are not uncommon for physician telephone surveys. A physician survey
carried out in 12 countries assessing their knowledge and application of COPD showed that
contacting physicians by telephone had low response rate (USA 10%, Italy 21%) [26]. A tele-
phone survey amongst neurologists in 12 European countries to assess awareness of clinical
guidelines had a response rate of 27.2% [27]. Low response rates also occur in chart review
studies, with 10% of invited physicians participating in a US-based community chart review
study [28], and 34% of invited urologists participating in a retrospective on-line chart review
[29].
The sampling list used for the physicians’ survey and Round 1 of chart review was based on
a medical marketing database and included physician contact details that were not filtered by
specialty. The inclusion of physicians who were not oncologists in the initial study population
may give an underestimate of the true response rate observed in the study. For Round 2 of the
chart review study a more targeted method of sampling was used where the medical marketing
database was filtered by specialty. With the different sampling methods used and the similari-
ties in baseline characteristics of physicians between rounds, the results are considered to be
representative of oncologist prescribing practice in Europe and any perceived selection bias
resulting from the low response rate is unlikely to be impacting the study results.
Responding and non-responding physicians have been found to have similar demographic
characteristics, perhaps due to the high level of homogeneity in the physician population (com-
parable education, socio-economic status, etc.) [30]. In the physician survey, more participat-
ing oncologists had10 years’ experience (62.1% [187/301] vs 42.7% [44/103], respectively)
and had treated40 mCRC patients in the previous quarter (58.1% [175/301] vs 12.6% [13/
103], respectively) than screened oncologists who were not eligible for the study. Approxi-
mately three quarters of physicians could recall receiving educational materials on KRAS test-
ing and this result was encouraging. Overall, we consider that the participating oncologists
were likely to be representative of those treating mCRC patients in the EU.
Within the EU, individual countries are likely to have their own strategies for improving the
care of patients with mCRC. In general there should be equal access to treatments and a need
to develop platforms that enable patients to receive the most appropriate treatment (e.g. molec-
ular genetics and testing). Within individual countries, the proportion of patients treated in
each type of facility (institution / hospital / private practice) will differ, and the use of KRAS
testing may also vary between facility types. In the physician survey, we have shown that by
2012, the percentage of participating physicians adopting tumor KRAS testing was nearly 100%
in Europe. Previous physician surveys in 2010 following published guidance recommending
the adoption of KRAS testing prior to EGFR-targeted treatment [18,19] found that the range of
adoption varied widely (20–100%) across countries [20–22]. In Europe in 2010, physicians
used clinical judgment when deciding whether or not to test mCRC KRAS status prior to treat-
ment with EGFR-targeted therapies, with 73% of participating physicians testing mCRC KRAS
status prior to prescribing EGFR-targeted therapies [20]. Of those specialists who did not test
KRAS status, reasons cited were that the tests were not considered relevant for the patients
(47%) or the specialist was unfamiliar with the test (40%) [21]. In Round 3 of the physician sur-
vey, more information regarding influencing factors will be collected to gain as much insight as
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possible into why, on rare occasions, physicians might prescribe panitumumab to patients with
mutant or unknown RAS tumor status.
The data we report in our medical records review are supported by previous studies, which
showed that, in 2010, physicians were beginning to adopt KRAS testing prior to EGFR-targeted
treatment following published guidance [23,24]. Of those specialists in France who did not test
KRAS status, reasons for not testing were that the patient had received prior anti-EGFR-treat-
ment (63% of patients) or there was an absence of tumor/technical issues (27% of patients)
[23]. Interestingly, in the US in 2010, of those patients with mutant KRAS tumor status, only
86% were not treated with EGFR-targeted therapies [24], suggesting that 14% received anti-
EGFR-treatment. In comparison, by 2012 in our medical records review, 1% (3/302) of patients
tested for KRAS tumor status prior to their first dose of panitumumab had mutant or unknown
KRAS status (none were receiving concurrent oxaliplatin-containing therapy).
We have shown that by 2012 in Europe, there was a high level of knowledge amongst oncol-
ogists around the need to test and confirm patients’mCRC tumors as being wild-type for
KRAS prior to treatment with panitumumab, with or without concurrent oxaliplatin-contain-
ing therapy. Nearly all oncologists surveyed followed the licensed indication for panitumumab,
but a minority still used their clinical judgment when deciding whether to treat patients with
mutant or unknown KRASmCRC status. While their decisions conflict with current prescrib-
ing information, discussions between individual physicians and their patients around the risks
and benefits (e.g. additional biopsy, denial of treatment) may contribute to these decisions.
Both studies report very good compliance with the licensed indication for panitumumab in
terms of KRAS testing at the time of Rounds 1 and 2 of the studies. There was also a very good
level of knowledge amongst oncologists around the need to test and confirm wild-type KRAS
tumor status prior to treatment with panitumumab, with or without concurrent oxaliplatin-
containing therapy. Nearly all patients treated with panitumumab (with or without concurrent
oxaliplatin-containing therapy) had wild-type KRAS tumor status confirmed prior to first
dose. It is important that tests for predictive molecular markers such as KRAS are carried out
using validated tests in accredited laboratories that have quality controls in place. All partici-
pating laboratories used a CE-marked or otherwise validated KRAS detection method, and
nearly all participated in a QA scheme.
In Round 3 of the physician survey and medical records review, which is evaluating knowl-
edge of the need to test for an expanded number of RASmutations prior to treating with pani-
tumumab, the physician questionnaires will capture additional free-text details to describe the
oncologists’ rationale that led to patients with mutant or unknown tumor RAS status receiving
panitumumab. Distribution of the educational materials continues. Data from Round 3 for
both studies evaluating RAS testing are awaited with interest.
Acknowledgments
The authors would like to thank and acknowledge all of the physicians who participated in the
physician survey and in the medical records review study. In addition, we would like to thank
the following for their contributions to the two studies and this article: James Bennett MSc
(Amgen Ltd) for statistical support; Rachel Bowman BSc and Paul Knowles BSc (Amgen Ltd)
for SAS programming support; Paula Haynes BSc RGN and Pari Parker BSc (Amgen Ltd) for
study management support; Adelphi Research for conduct and data management of the Physi-
cian Survey study; Quintiles for data management of the Medical Records Review study; Caro-
lyn Bowler PhD (Bioscript Medical Ltd) for medical writing assistance (funded by Amgen Ltd).
Panitumumab Use and KRAS Testing in mCRC
PLOSONE | DOI:10.1371/journal.pone.0140717 October 22, 2015 13 / 15
Author Contributions
Conceived and designed the experiments: GD AT. Performed the experiments: J. Trojan LM J.
Tomášek PGA GA. Analyzed the data: JHVK GK GD JHT AT. Wrote the paper: J. Trojan LM
J. Tomášek ER PF GDM PGA GA JHVK AT GK GD JHT.
References
1. Bokemeyer C, Bondarenko I, Makhson A, Hartmann JT, Aparicio J, et al. (2009) Fluorouracil, leucov-
orin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal can-
cer. J Clin Oncol 27: 663–671. doi: 10.1200/JCO.2008.20.8397 PMID: 19114683
2. CunninghamD, Humblet Y, Siena S, Khayat D, Bleiberg H, et al. (2004) Cetuximab monotherapy and
cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351:
337–345. PMID: 15269313
3. Jonker DJ, O'Callaghan CJ, Karapetis CS, Zalcberg JR, Tu D, et al. (2007) Cetuximab for the treatment
of colorectal cancer. N Engl J Med 357: 2040–2048. PMID: 18003960
4. Sobrero AF, Maurel J, Fehrenbacher L, Scheithauer W, Abubakr YA, et al. (2008) EPIC: phase III trial
of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic
colorectal cancer. J Clin Oncol 26: 2311–2319. doi: 10.1200/JCO.2007.13.1193 PMID: 18390971
5. Van Cutsem E, Köhne CH, Hitre E, Zaluski J, Chang Chien CR, et al. (2009) Cetuximab and chemo-
therapy as initial treatment for metastatic colorectal cancer. N Engl J Med 360: 1408–1417. doi: 10.
1056/NEJMoa0805019 PMID: 19339720
6. Van Cutsem E, Peeters M, Siena S, Humblet Y, Hendlisz A, et al. (2007) Open-label phase III trial of
panitumumab plus best supportive care compared with best supportive care alone in patients with che-
motherapy-refractory metastatic colorectal cancer. J Clin Oncol 25: 1658–1664. PMID: 17470858
7. Wilke H, Glynne-Jones R, Thaler J, Adenis A, Preusser P, et al. (2008) Cetuximab plus irinotecan in
heavily pretreated metastatic colorectal cancer progressing on irinotecan: MABEL Study. J Clin Oncol
26: 5335–5343. doi: 10.1200/JCO.2008.16.3758 PMID: 18854570
8. Amado RG,Wolf M, Peeters M, Van Cutsem E, Siena S, et al. (2008) Wild-type KRAS is required for
panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 26: 1626–1634. doi:
10.1200/JCO.2007.14.7116 PMID: 18316791
9. Benvenuti S, Sartore-Bianchi A, Di Nicolantonio F, Zanon C, Moroni M, et al. (2007) Oncogenic activa-
tion of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-
epidermal growth factor receptor antibody therapies. Cancer Res 67: 2643–2648. PMID: 17363584
10. De RoockW, Piessevaux H, De Schutter J, Janssens M, De Hertogh G, et al. (2008) KRAS wild-type
state predicts survival and is associated to early radiological response in metastatic colorectal cancer
treated with cetuximab. Ann Oncol 19: 508–515. PMID: 17998284
11. Di Fiore F, Blanchard F, Charbonnier F, Le Pessot F, Lamy A, et al. (2007) Clinical relevance of KRAS
mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy. Br J Can-
cer 96: 1166–1169. PMID: 17375050
12. Freeman DJ, Juan T, Reiner M, Hecht JR, Meropol NJ, et al. (2008) Association of K-ras mutational sta-
tus and clinical outcomes in patients with metastatic colorectal cancer receiving panitumumab alone.
Clin Colorectal Cancer 7: 184–190. doi: 10.3816/CCC.2008.n.024 PMID: 18621636
13. Jimeno A, Messersmith WA, Hirsch FR, Franklin WA, Eckhardt SG (2009) KRASmutations and sensi-
tivity to epidermal growth factor receptor inhibitors in colorectal cancer: practical application of patient
selection. J Clin Oncol 27: 1130–1136. doi: 10.1200/JCO.2008.19.8168 PMID: 19124802
14. Karapetis CS, Khambata-Ford S, Jonker DJ, O'Callaghan CJ, Tu D, et al. (2008) K-ras mutations and
benefit from cetuximab in advanced colorectal cancer. N Engl J Med 359: 1757–1765. doi: 10.1056/
NEJMoa0804385 PMID: 18946061
15. Lievre A, Bachet JB, Boige V, Cayre A, Le Corre D, et al. (2008) KRASmutations as an independent
prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol 26:
374–379. doi: 10.1200/JCO.2007.12.5906 PMID: 18202412
16. Douillard JY, Siena S, Cassidy J, Tabernero J, Burkes R, et al. (2010) Randomized, phase III trial of
panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4
alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the
PRIME study. J Clin Oncol 28: 4697–4705. doi: 10.1200/JCO.2009.27.4860 PMID: 20921465
17. Peeters M, Price TJ, Cervantes A, Sobrero AF, Ducreux M, et al. (2010) Randomized phase III study of
panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as
second-line treatment in patients with metastatic colorectal cancer. J Clin Oncol 28: 4706–4713. doi:
10.1200/JCO.2009.27.6055 PMID: 20921462
Panitumumab Use and KRAS Testing in mCRC
PLOSONE | DOI:10.1371/journal.pone.0140717 October 22, 2015 14 / 15
18. Van Cutsem E, Nordlinger B, Cervantes A (2010) Advanced colorectal cancer: ESMOClinical Practice
Guidelines for treatment. Ann Oncol 21 Suppl 5: v93–v97. doi: 10.1093/annonc/mdq222 PMID:
20555112
19. National Comprehensive Cancer Network (2009) Clinical practice guidelines in oncology: colon cancer.
http://wwwnccnorg/professionals/physician_gls/PDF/colonpdf.
20. Ciardiello F, Tejpar S, Normanno N, Mercadante D, Teague T, et al. (2011) Uptake of KRASmutation
testing in patients with metastatic colorectal cancer in Europe, Latin America and Asia. Target Oncol 6:
133–145. doi: 10.1007/s11523-011-0181-x PMID: 21630045
21. Cox SL, Zlot AI, Silvey K, Elliott D, Horn T, et al. (2012) Patterns of cancer genetic testing: a randomized
survey of Oregon clinicians. J Cancer Epidemiol 2012: 294730. doi: 10.1155/2012/294730 PMID:
23150730
22. Harris JN, Liljestrand P, Alexander GL, Goddard KA, Kauffman T, et al. (2013) Oncologists' attitudes
toward KRAS testing: a multisite study. Cancer Med 2: 881–888. doi: 10.1002/cam4.135 PMID:
24403261
23. Smith D, Rouyer M, Francois E, Mitry E, Monnereau A, et al. (2011) Use of cetuximab in a real-life set-
ting in France with respect to KRAS status: Preliminary results of EREBUS cohort study. J Clin Oncol
29: Abstract e14094.
24. Webster J, Kauffman TL, Feigelson HS, Pawloski PA, Onitilo AA, et al. (2013) KRAS testing and epider-
mal growth factor receptor inhibitor treatment for colorectal cancer in community settings. Cancer Epi-
demiol Biomarkers Prev 22: 91–101. doi: 10.1158/1055-9965.EPI-12-0545 PMID: 23155138
25. Francke AL, Smit MC, de Veer AJ, Mistiaen P (2008) Factors influencing the implementation of clinical
guidelines for health care professionals: a systematic meta-review. BMCMed Inform Decis Mak 8: 38.
doi: 10.1186/1472-6947-8-38 PMID: 18789150
26. Davis KJ, Landis SH, Oh YM, Mannino DM, Han MK, et al. (2015) Continuing to Confront COPD Inter-
national Physician Survey: physician knowledge and application of COPDmanagement guidelines in
12 countries. Int J Chron Obstruct Pulmon Dis 10: 39–55. doi: 10.2147/COPD.S70162 PMID:
25565799
27. Lledo A, Dellva MA, Strombom IM, Wilkie JL, Jungemann ME, et al. (2007) Awareness of potential val-
vulopathy risk with pergolide and changes in clinical practice after label change: a survey among Euro-
pean neurologists. Eur J Neurol 14: 644–649. PMID: 17539942
28. Goldberg SL, Chen L, Guerin A, Macalalad AR, Liu N, et al. (2013) Association between molecular
monitoring and long-term outcomes in chronic myelogenous leukemia patients treated with first line
imatinib. Curr Med Res Opin 29: 1075–1082. doi: 10.1185/03007995.2013.812034 PMID: 23738923
29. Witjes JA, Palou J, Soloway M, LammD, Kamat AM, et al. (2013) Current clinical practice gaps in the
treatment of intermediate- and high-risk non-muscle-invasive bladder cancer (NMIBC) with emphasis
on the use of bacillus Calmette-Guerin (BCG): results of an international individual patient data survey
(IPDS). BJU Int 112: 742–750. doi: 10.1111/bju.12012 PMID: 23452187
30. Kellerman SE, Herold J (2001) Physician response to surveys. A review of the literature. Am J Prev
Med 20: 61–67.
Panitumumab Use and KRAS Testing in mCRC
PLOSONE | DOI:10.1371/journal.pone.0140717 October 22, 2015 15 / 15
